Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

van, de, Munckhof, A; Lindgren, E; Kleinig, TJ; Field, TS; Cordonnier, C; Krzywicka, K; Poli, S; Sánchez, van, Kammen, M; Borhani-Haghighi, A; Lemmens, R; Scutelnic, A; Ciccone, A; Gattringer, T; Wittstock, M; Dizonno, V; Devroye, A; Elkady, A; Günther, A; Cervera, A; Mengel, A; Chew, BLA; Buck, B; Zanferrari, C; Garcia-Esperon, C; Jacobi, C; Soriano, C; Michalski, D; Zamani, Z; Blacquiere, D; Johansson, E; Cuadrado-Godia, E; Vuillier, F; Bode, FJ; Caparros, F; Maier, F; Tsivgoulis, G; Katzberg, HD; Duan, J; Burrow, J; Pelz, J; Mbroh, J; Oen, J; Schouten, J; Zimmermann, J; Ng, K; Garambois, K; Petruzzellis, M; Carvalho, Dias, M; Ghiasian, M; Romoli, M; Miranda, M; Wronski, M; Skjelland, M; Almasi-Dooghaee, M; Cuisenier, P; Murphy, S; Timsit, S; Coutts, SB; Schönenberger, S; Nagel, S; Hiltunen, S; Chatterton, S; Cox, T; Bartsch, T; Shaygannejad, V; Mirzaasgari, Z; Middeldorp, S; Levi, MM; Kremer, Hovinga, JA; Jood, K; Tatlisumak, T; Putaala, J; Heldner, MR; Arnold, M; Aguiar, de, Sousa, D; Ferro, JM; Coutinho, JM, , Cerebral, Venous, Sinus, Thrombosis, With, Thrombocytopenia, Syndrome, Study, Group.
Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.
Stroke. 2022; 53(10): 3206-3210. Doi: 10.1161/STROKEAHA.122.039575 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Gattringer Thomas

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. METHODS: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0-2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). RESULTS: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94-194). Two patients died during follow-up (3% [95% CI, 1%-11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%-94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). CONCLUSIONS: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.

Find related publications in this database (using NLM MeSH Indexing)

Adult - administration & dosage

COVID-19 - prevention & control

COVID-19 Vaccines - adverse effects

Cerebral Hemorrhage - administration & dosage

Female - administration & dosage

Humans - administration & dosage

Intracranial Thrombosis - diagnosis

Male - administration & dosage

Risk Factors - administration & dosage

SARS-CoV-2 - administration & dosage

Thrombocytopenia - administration & dosage

Thrombosis - administration & dosage

Vaccines - administration & dosage

Venous Thrombosis - administration & dosage

Find related publications in this database (Keywords)

hospitalization

intracranial thrombosis

mortality

thrombocytopenia

vaccination

venous thrombosis

© Med Uni Graz • Imprint